A review on the clinical use of inhaled amphotericin B

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 22, Issue 3, 2009, Pages 213-227

  Kuiper, Laura ^a,b   Ruijgrok, Elisabeth J ^b  

^a IKAZIA HOSPITAL   (Netherlands)

^b Maasstad Hospital Rotterdam   (Netherlands)

Author keywords

Aerosol; Amphotericin B; Nebulization

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOSPORIN; FLUCONAZOLE; ITRACONAZOLE; NYSTATIN; PLACEBO; PREDNISOLONE; PYRROLE; PYRROLE DERIVATIVE;

BRONCHOPULMONARY ASPERGILLOMA; BRONCHOSPASM; COUGHING; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FORCED EXPIRATORY VOLUME; FUNGAL COLONIZATION; HISTOPLASMOSIS; HUMAN; LUNG ASPERGILLOSIS; LUNG MYCOSIS; LUNG TRANSPLANTATION; MUCORMYCOSIS; NAUSEA; NAUSEA AND VOMITING; NEBULIZATION; NEUTROPENIA; PLEURA EMPYEMA; PULMONARY CANDIDIASIS; REVIEW; SIDE EFFECT; TASTE DISORDER; TRACHEOBRONCHITIS; VOMITING;

ADMINISTRATION, INHALATION; AMPHOTERICIN B; HUMANS; LUNG TRANSPLANTATION; MYCOSES; NEBULIZERS AND VAPORIZERS; NEUTROPENIA;

EID: 70349288408     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2008.0715     Document Type: Review

References (90)

1. Pfaller MA, Pappas PG, and Wingard JR: Invasive fungal pathogens: Current epidemiological trends. Clin Infect Dis. 2006;43:S3-S14.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, and Edmond MB: Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317.
3. Trick WE, Fridkin SK, Edwards JR, Hajjeh A, Gaynes RP, and the National Nosocomial Infections Surveillance System Hospitals: Secular trend of hospital-acquired candidemia among intensive care unit patients in the united states during 1989-1999. Clin Infect Dis. 2002;35:627-630.
4. Denning DW: Invasive aspergillosis (review). Clin Infect Dis. 1998;26:781-805.
5. Marr KA, Carter RA, Crippa F, Wald A, and Corey L: Epidemiology and outcome of mould infections in hematopoi-etic stem cell transplant recipients. Clin Infect Dis. 2002;34: 909-917. (Pubitemid 34229758)
6. Baddley JW, Stroud TP, Salzman D, and Pappas PG: Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001;32:1319-1324.
7. Tomee JF, and van der Werf TS: Pulmonary aspergillosis. Neth J Med. 2001;59:244-258.
8. Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, and McCurry KR: Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis. 2006;8:213-218.
9. Burik JA van: Role of new antifungal agents in prophylaxis of mycoses in high risk patients. Curr Opin Infect Dis. 2005;18:479-483.
10. Pound MW, Drew RH, and Perfect JR: Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. Curr Opin Infect Dis. 2002;15:183-194.
11. Bhatti Z, Shaukat A, Almyroudis NG, and Segal BH: Review of epidemiology, diagnosis, and treatment of invasive, mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia. 2006;162:1-15.
12. Deray G: Amphotericin B nephrotoxicity. J Antimicrob Chemother. 2002;49(Suppl S1):37-41. (Pubitemid 34162655)
13. Schmitt HJ: New methods of delivery of amphotericin B. Clin Infect Dis. 1993;17(Suppl 2):S501-S506.
14. Beyer J, Schwartz S, Barzen G, Risse G, Dullenkopf C, Weyer C, and Siegert W: Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis. Infection. 1994;22:143-148.
15. Beyer J, Schwartz S, Heinemann V, and Siegert W: Strategies in prevention of invasive pulmonary aspergillosis in imunnosuppressed or neutropenic patients. Antimicrob Agent Chemother. 1994;37:911-917.
16. Nicod LP, Pache JC, and Howarth N: Fungal infections in transplant recipients. Eur Respir J. 2001;17:133-140.
17. Drew R: Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents. 2006; 27(Suppl 1):36-44.
18. Vyas SP, Quraishi S, Gupta S, and Jaganathan KS: Aero-solized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm. 2005;296:12-25.
19. Cicogna CE, White MH, Bernard EM, Ishimura T, Sun M, Tong WP, and Armstrong D: Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agent Chemother. 1997; 41:259-261.
20. Sorensen KN, Allent SD, Nejd MJ, and Proffitt RT: Aerosolization of liposomal (Ambisome®) and non-liposo-mal (Fungizone®) amphotericin B as a treatment for pulmonary fungal infections. J Controlled Rel. 1994;28:346-347.
21. Ruijgrok EJ, Vulto AG, and Van Etten EW: Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): Aerosol characteristics and in-vivo amphotericin B deposition in rats. J Pharm Pharmacol. 2000;52:619-627.
22. Allen SD, Sorensen KN, Nejdl MJ, Durrant C, and Proffit RT: Prophylactic efficacy of aerosolized liposomal (Ambi-some®) and non-liposomal (Fungizone®) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother. 1994;34:1001-1013.
23. Schmitt HJ, Bernard EM, Hauser M, and Armstrong D: Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agent Chemother. 1988;32:1676-1679.
24. Allen SD, Sorensen KN, Nejd MJ, and Proffitt RT: Efficacy of aerosolized liposomal amphotericin B (Ambisome®) as a prophylactic treatment in an immune compromised murine model of pulmonary aspergillosis. J Controlled Rel. 1994; 28:348-349.
25. Ruijgrok EJ, Vulto AG, and van Etten WM: Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary as-pergillosis in severely immunocompromized rats. J Antimi-crob Chemother. 2001;48:89-95.
26. Gavalda J, Martin MT, López P, Gomis X, Ramirez JL, Ro-dríguez D, Len O, Puigfel Y, Ruíz I, and Pahissa A: Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agent Chemother. 2005;49:3028-3030.
27. Gilbert BE: Liposomal aerosols in the management of pulmonary infections. J Aerosol Med. 1996;9:111-122.
28. Ruijgrok EJ, Fens MHA, Bakker-Woudenberg IAJM, van Et-ten EWM, and Vulto AG: Nebulization of four commercially available amphotericin B formulations in persistently gran-ulocytopenic rats with invasive pulmonary aspergillosis: Evidence for long-term biological activity. J Pharm Pharmacol. 2005;57:1289-1295.
29. Olson JA, Adler-Moore JP, Schwartz J, Jensen GM, and Prof-fitt RT: Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemo-ther. 2006;50:2122-2131.
30. Ho KM, Duff O, Chambers D, and Murray R: Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals. Transpl Infect Dis. 2008;10:168-176.
31. Kilburn KH: The innocuousness and possible therapeutic use of aerosol amphotericin B. Am Rev Respir Dis. 1959;80: 441-442.
32. Carveth JH, and Kanner RE: Optimizing deposition of aerosolized drug in the lung: A review. Medscape Respir Care. 1999. www.medscape.com/viewarticle/ 408738.
33. Diot P, Dequin PF, Rivoire B, Gagnadoux F, Faurisson F, Diot E, Boissinot E, Le Pape A, Palmer L, and Lemarie E: Aerosols and anti-infectious agents. J Aerosol Med. 2001;14:55-64.
34. Dalby RN, Tiano SL, and Hickey AJ: Mechanical devices for the delivery of therapeutic aerosols to the lungs. In: Hickey AJ (ed). Inhalation aerosols. Marcel Dekker, Inc., New York; pp. 441-473, 1996.
35. Diot P, Rivoire B, Le Pape A, Lemarie E, Dire D, Furet Y, Breteau M, and Smaldone GC: Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Respir J. 1995;8:1263-1268.
36. Roth C, Gebhart J, Just-NÅbling G, Eisenhart-Rothe B von, and Beinhauer-Reeb I: Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillo-sis. Infection. 1996;24:354-360.
37. Corcoran TE, Venkataramanan R, Mihelc KM, Marcin-kowski AL, Ou J, McCook BM, Weber L, Carey ME, Paterson DL, Pilewski JM, McCurry KR, and Husain S: Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant. 2006;6:2765-2773.
38. Shah SP, and Misra A: Development of liposomal ampho-tericin B dry powder formulation. Drug Deliv. 2004;11:247-253. (Pubitemid 39096043)
39. Kirkpatrick WR, Najvar LK, Vallor AC, Bocanegra R, Pfeif-fer J, Perkins K, Kugler AR, Sweeney TD, Graybill JR, and Patterson TF: Prophylactic dosing of NKTR-024 (formerly amphotericin B inhalation powder, ABIP) in a Guinea pig model of invasive pulmonary aspergillosis (IPA). Of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology:Chicago;ab-stract n. M-1849.
40. Le Brun PPH, de Boer AH, Gjaltema D, Hagedoorn P, Hei-jerman HG, and Frijlink HW: Inhalation of tobramycin in cystic fibrosis Part 1: The choice of a nebulizer. Int J Pharm. 1999;189:205-214.
41. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Löwenberg B, Vulto A, Lugten-burg PJ, and de Marie S: Aerosolized liposomal ampho-tericin B for the prevention of invasive pulmonary as-pergillosis during prolonged neutropenia: A randomized placebo-controlled trial. Clin Infect Dis. 2008;46:1401-1408.
42. Marra F, Patrovi N, Wasan KM, Kwong EH, Ensom MH, Cassidy SM, Fradet G, and Levy RD: Amphotericin B disposition after aerosol inhalation in lung transplant recipients. Ann Pharmaceother. 2002;36:46-51.
43. Montforte V, Roman A, Gavalda J, Lopez R, Pou L, Simo M, Aguade S, Soriano B, Bravo C, and Morell F: Nebulized am-photericin B concentrations and distribution in the respiratory tract of lung transplanted patients. Transplantation. 2003;75:1571-1574.
44. Beyer J, Barzen G, Risse G, Weyer C, Miksits K, Dullenkopf K, Huhn D, and Siegert W: Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 1993;37:1367-1369. (Pubitemid 23166742)
45. Myers SE, Devine SM, Topper RL, Ondrey M, Chandler C, O'Toole K, Williams SF, Larson RA, and Geller RB: A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma. 1992; 8:229-233.
46. Calvo V, Borro JM, Morales P, Morcillo A, Vicente R, Tar-razona V, and Paris F: Antifungal prophylaxis during the early postoperative period of lung transplantation. Chest. 1999;115:1301-1304.
47. Montforte V, Roman A, Gavalda J, Bravo C, Tenorio L, Ferrer A, Maestre J, and Morell F: Nebulized amphotericin B prophylaxis for aspergillus infections in lung transplantation: A study of risk factors. J Heart Lung Transplant. 2001; 20:1274-1281.
48. Reichenspurner H, Gamberg P, Nitschke M, Valantine H, Hunt S, Oyer PE, and Reitz BA: Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc. 1997;29:627-628.
49. Drew RH, Dodds Ashley A, Benjamin DK Jr, Duane Davis R, Palmer SM, and Perfect JR: Comparative safety of am-photericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation. 2004;77:232-237.
50. Palmer SM, Drew RH, Whitehouse JD, Tapson VF, Davis RD, McConnell RR, Kanj SS, and Perfect RR: Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation. 2001;72:545-548.
51. Dummer JS, Lazariashvilli N, Barnes J, Ninan M, and Mil-stone AP: A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant. 2004;23:1376-1381.
52. Perfect JR, Dodds Ashley E, and Drew R: Design of aerosolized amphotericin B formulations for prophylaxis trials among lung transplant recipients. Clin Infect Dis. 2004;39(Suppl 4):S207-S210.
53. Klepser ME: Amphotericin B in lung transplant recipients. Ann Pharmacother. 2002;36:167-169.
54. Kanj S, Welty-Wolf K, Madden J, Tapson V, Baz MA, Davis RD, and Perfect JR: Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of literature. Medicine. 1996;75:142-156.
55. Mohammad RA, and Klein KC: Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections. Ann Pharmacother. 2006;40:2148-2154.
56. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, and Angulo-Gonzalez D: Posaconazole vs. Fluconazole or itraconazole prophylaxis in patients with neutropenia. N Eng J Med. 2007;356:348-359.
57. Laurenzi A de, Matteocci A, Lanti A, Pescador L, Blandino F, and Papetti C: Amphotericin B prophylaxis against invasive fungal infections in neutropenic patients: A single center experience from 1980 to 1995. Infection. 1996;24:361-366.
58. Conneally E, Cafferkey MT, Daly PA, Keane CT, and McCann SR: Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant. 1990;5:403-406.
59. Hertenstein B, Kern WV, Schmeiser T, Stefanic M, Bunjes D, Wiesneth M, Novotny J, Heimpel H, and Arnold R: Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol. 1994;68:21-26.
60. Meyers JD: Fungal infections in bone marrow transplantations. Semin Oncol. 1990;17(Suppl 6):10-13.
61. Erjavec Z, Woolthuis GM, de Vries-Hospers HG, Sluiter WJ, Daenen SM, de Pauw B, and Halie MR: Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis. 1997;16:364-368.
62. Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, Trittin A, Kern WV, Boenisch O, Bosse D, Lenz K, Ludwig WD, Hiddeman W, Siegert W, and Beyer J: Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial. Blood. 1999;93:3654-3661.
63. Castagnola E, Moresco L, Cappelli B, Cuzzubbo D, Moroni C, Lanino E, and Faraci M: Nebulized liposomal ampho-tericin B and combined systemic antifungal therapy for the treatment of severe pulmonary aspergillosis after allogeneic hematopoietic stem cell transplant for a fatal mitochondrial disorder. J Chemother. 2007;19:339-342.
64. Tillie-Leblond I, and Tonnel AB: Allergic bronchopul-monary aspergillosis. Allergy. 2005;60:1004-1013.
65. Casey P, Garrett J, and Eaton T: Allergic bronchopulmonary aspergillosis in a lung transplant patient successfully treated with nebulized amphotericin. J Heart Lung Transplant. 2002;21:1237-1241.
66. Tiddens HA, Pfaff SJ, van der Zander T, and Ruijgrok EJ: Weekly nebulization of liposomal amphotericin B for the treatment of prednisone dependent ABPA. Pediatr Pul-monol. 2003;Suppl 25:301.
67. Elphick H, and Southern K: Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2000;4:CD002204.
68. Suzuki K, Iwata S, and Iwata H: Allergic bronchopulmonary aspergillosis in a 9-year-old boy. Eur J Pediatr. 2002;161: 408-409.
69. Laoudi Y, Paolini JB, Grimfeld A, and Just J: Nebulised cor-ticosteroid and amphotericin B: An alternative treatment for ABPA? Eur Respir J. 2008;31:908-909.
70. Purcell IF, and Corris PA: Use of nebulised liposomal am-photericin B in the treatment of Aspergillus fumigatus empyema. Thorax. 1995;50:1321-1323.
71. Birsan T, Taghavi S, and Klepetko W: Treatment of as-pergillus-related ulcerative tracheobronchitis in lung transplant recipients. J Heart Lung Transplant. 1998;17:437-438.
72. Boots RJ, Paterson DL, Allworth AM, and Faoagali JL: Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal ampho-tericin, inhaled amphotericin B, gamma interferon and GM-CSF. Thorax. 1999;54:1047-1049.
73. Dal Conte I, Riva G, Obert R, Lucchini A, Bechis G, De Rosa G, and Gioannini P: Tracheobronchial aspergillosis in a patient with AIDS treated with aerosolized amphotericin B combined with itraconazole. Mycoses. 1996;39:371-374.
74. Palmer SM, Perfect JR, Howell DN, Lawrence CM, Miralles AP, Davis RD, and Tapson VF: Candidal anastomotic infection in lung transplant recipients: Successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant. 1998;17:1029-1033.
75. Oehling A, Giron M, and Subira ML: Aerosol chemotherapy in bronchopulmonary candidiasis. Respiration. 1975;32:179-184.
76. Safdar A, O'Brien S, and Kouri IF: Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspo-fungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant. 2004;34:467-468.
77. Knechtel SA, and Klepser ME: Safety of aerosolized am-photericin B. Review. Expert Opin Drug Saf. 2007;6:523-532.
78. Griese M, Schams A, and Lohmeier KP: Amphotericin B and pulmonary surfactant. Eur J Med Res. 1998;3:383-386.
79. Dubois J, Bartter T Gryn J, and Pratter MR: The physiologic effects of inhaled amphotericin B. Chest. 1995;108:750-753.
80. Gryn J, Goldberg J, Johnson E, Siegel J, and Inzerillo J: The toxicity of daily inhaled amphotericin B. Am J Clin Oncol. 1993;16:43-46.
81. Ruiz I, Molina I, Gavaldà J, Bueno J, Barrenetxea C, Zuazu J, Bastida P, Julià A, Sánchez de Toledo J, and Pahisaas A: Safety and tolerability of nebulized liposomal amphotericin B in hematologic patients. Abstract program of the 45th In-terscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology: Washington, DC; abstract no. M-977-2005, 2005.
82. Alexander BD, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, and Perfect JR: Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2006;8:13-20.
83. Lowry CM, Marty FM, Vargas SO, Lee JT, Fiumara K, Deykin A, and Baden LR: Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: A retrospective study. Transpl Infect Dis. 2007; 9:121-125.
84. Schreier H, Gonzalez-Rothi RJ, and Stecenko AA: Pulmonary delivery of liposomes. J Controlled Rel. 1993;24:209-223.
85. Riedel A, Choe L, Inciardi J, Yuen C, Martin T, and Guglielmo BJ: Antifungal prophylaxis in chemotherapy-associated neutropenia: A retrospective observational study. BMC Infect Dis. 2007;7:70.
86. Husain S, Paterson DL, Studer S, Pilweski J, Crespo M, Zal-donis D, Shutt K, Pakstis DL, Zeevi A, Johnson B, Kwak EJ, and McCurry KR: Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6:3008-3016. (Pubitemid 44777932)
87. Chou LS, Lewis RE, Ippoliti C, Champlin RE, and Kon-toyiannis DP: Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy. 2007;27:1644-1650.
88. Burik JAH van, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, and Walsh TJ: Micafungin versus flucona-zole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407-1416.
89. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'Brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Nebiyou Bekele B, Leitz GJ, Lopez-Roman I, and Estey EH: Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agent Chemother. 2006;50:143-147.
90. Ullmann AJ, and Cornely OA: Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis. 2006;19:571-576.